胸腺肽在慢性阻塞性肺疾病急性加重期临床治疗中的作用

目的:评估胸腺肽在慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)临床治疗中的应用价值。方法:将75例AECOPD患者随机分为实验组(n=38)和对照组(n=37),两组均给予COPD常规治疗,实验组在此基础上静脉滴注胸腺肽,疗程为14 d。比较两组治疗效果,观察治疗前后血气分析指标、肺功能指标及细胞免疫指标的变化。结果:实验组治疗总有效率高达92.11%,高于对照组的72.97%(P<0.05)。两组治疗后动脉血氧分压(PaO_2)、动脉二氧化碳分压(PaCO_2)、第1秒呼气容积(FEV1)、第1秒用力呼气容积占用力肺活量比值(FEV1/FVC)指标均较治疗前明显改善,且实验组各指标改善程度优于对照组(P<0.05或P<0.01)。两组治疗后CD_4~+、CD_4~+/CD_8~+水平较治疗前明显升高,CD_8~+明显降低,且实验组升高及降低程度均大于对照组(P<0.05或P<0.01)。结论:在常规治疗基础上加用胸腺肽能有效缓解AECOPD患者临床症状,增强细胞免疫功能。

Effect of thymosin in the clinical treatment of acute exacerbation of chronic obstructive pulmonary disease

Objective:To evaluate the application value of thymosin in the clinical treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods:A total of 75 patients with AECOPD were randomly divided into experiment group (n =38) and control group (n =37).Both groups were treated with routine therapies for chronic obstructive pulmonary disease (COPD),on which basis experiment group was added with intravenous injection of thymosin,for totally 14 d.Therapeutic efficacy was compared between two groups,and the changes of blood-gas analytic indexes,lung function indexes and cellular immunity indexes were observed before and after treatment.Results:The total response rate was 92.11％ in experiment group,evidently higher than the 72.97％ in control group (P ＜ 0.05).After treatment,arterial partial pressure of oxygen (PaO2,),arterial partial pressure of carbon dioxide (PaCO2),forced expiratory volume in one second (FEV1),and the ratio of FEV1 and forced vital capacity (FEV1/FVC) were improved notably,which changed more significantly in experiment group than those in control group (P ＜ 0.05 or P ＜ 0.01).After treatment,levels of CD4 + and CD4 +/CD8 + increased prominently while level of CD8 + decreased apparently than treatment before,which changed more significantly in experiment group than those in control group (P ＜ 0.05 or P ＜ 0.01).Conclusion:Application of thymosin on the basis of routine treatment can effectively improve the clinical symptoms and enhance the cellular immunity function of patients with AECOPD.